vs
Side-by-side financial comparison of Commercial Vehicle Group, Inc. (CVGI) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $154.8M, roughly 1.8× Commercial Vehicle Group, Inc.). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -5.2%). Commercial Vehicle Group, Inc. produced more free cash flow last quarter ($8.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -10.8%).
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CVGI vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.8M | $281.3M |
| Net Profit | — | $-128.5M |
| Gross Margin | 9.7% | 64.6% |
| Operating Margin | -1.2% | -43.0% |
| Net Margin | — | -45.7% |
| Revenue YoY | -5.2% | 39.4% |
| Net Profit YoY | — | -15.8% |
| EPS (diluted) | — | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.8M | $281.3M | ||
| Q3 25 | $152.5M | $265.2M | ||
| Q2 25 | $172.0M | $232.1M | ||
| Q1 25 | $169.8M | $203.5M | ||
| Q4 24 | $163.3M | $201.8M | ||
| Q3 24 | $171.8M | $191.5M | ||
| Q2 24 | $193.7M | $177.2M | ||
| Q1 24 | $194.6M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $-7.1M | $-92.7M | ||
| Q2 25 | $-4.8M | $-99.9M | ||
| Q1 25 | $-4.3M | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $9.5M | $-107.8M | ||
| Q2 24 | $-1.6M | $-102.6M | ||
| Q1 24 | $2.9M | $-115.0M |
| Q4 25 | 9.7% | 64.6% | ||
| Q3 25 | 10.5% | 64.7% | ||
| Q2 25 | 11.4% | 65.0% | ||
| Q1 25 | 10.5% | 63.3% | ||
| Q4 24 | 8.0% | 61.6% | ||
| Q3 24 | 9.6% | 61.1% | ||
| Q2 24 | 10.6% | 59.1% | ||
| Q1 24 | 11.9% | 61.2% |
| Q4 25 | -1.2% | -43.0% | ||
| Q3 25 | -0.7% | -37.3% | ||
| Q2 25 | 0.5% | -45.9% | ||
| Q1 25 | 0.8% | -54.6% | ||
| Q4 24 | -3.2% | -62.4% | ||
| Q3 24 | -0.6% | -61.3% | ||
| Q2 24 | 0.5% | -56.8% | ||
| Q1 24 | 2.3% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | -4.6% | -35.0% | ||
| Q2 25 | -2.8% | -43.0% | ||
| Q1 25 | -2.5% | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | 5.5% | -56.3% | ||
| Q2 24 | -0.8% | -57.9% | ||
| Q1 24 | 1.5% | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | — | $-0.74 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | — | $-0.88 | ||
| Q2 24 | $-0.05 | $-0.84 | ||
| Q1 24 | $0.09 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | $104.9M | $1.5B |
| Stockholders' EquityBook value | $133.4M | $-99.3M |
| Total Assets | $391.7M | $2.0B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | $104.9M | $1.5B | ||
| Q3 25 | $108.2M | $1.1B | ||
| Q2 25 | $118.2M | $1.1B | ||
| Q1 25 | $117.4M | $1.1B | ||
| Q4 24 | $135.5M | $1.1B | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $142.0M | — | ||
| Q1 24 | $155.7M | — |
| Q4 25 | $133.4M | $-99.3M | ||
| Q3 25 | $136.5M | $-354.5M | ||
| Q2 25 | $142.6M | $-305.5M | ||
| Q1 25 | $136.7M | $-250.8M | ||
| Q4 24 | $135.6M | $-139.6M | ||
| Q3 24 | $179.3M | $-60.1M | ||
| Q2 24 | $169.6M | $-1.6M | ||
| Q1 24 | $175.5M | $68.3M |
| Q4 25 | $391.7M | $2.0B | ||
| Q3 25 | $400.3M | $1.3B | ||
| Q2 25 | $429.8M | $1.3B | ||
| Q1 25 | $419.8M | $1.3B | ||
| Q4 24 | $424.6M | $1.5B | ||
| Q3 24 | $495.3M | $1.5B | ||
| Q2 24 | $503.2M | $1.6B | ||
| Q1 24 | $509.2M | $1.7B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | 0.72× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.89× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $8.7M | $-54.2M |
| FCF MarginFCF / Revenue | 5.6% | -19.3% |
| Capex IntensityCapex / Revenue | 2.3% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.3M | $-26.4M | ||
| Q3 25 | $-1.7M | $-35.4M | ||
| Q2 25 | $18.9M | $-60.3M | ||
| Q1 25 | $15.2M | $-62.7M | ||
| Q4 24 | $-26.6M | $-64.5M | ||
| Q3 24 | $-17.1M | $-51.1M | ||
| Q2 24 | $12.6M | $-94.0M | ||
| Q1 24 | $-2.4M | $-30.3M |
| Q4 25 | $8.7M | $-54.2M | ||
| Q3 25 | $-3.5M | $-45.8M | ||
| Q2 25 | $17.4M | $-65.9M | ||
| Q1 25 | $11.4M | $-67.1M | ||
| Q4 24 | $-30.6M | $-83.4M | ||
| Q3 24 | $-20.3M | $-55.3M | ||
| Q2 24 | $6.4M | $-99.1M | ||
| Q1 24 | $-7.4M | $-37.2M |
| Q4 25 | 5.6% | -19.3% | ||
| Q3 25 | -2.3% | -17.3% | ||
| Q2 25 | 10.1% | -28.4% | ||
| Q1 25 | 6.7% | -33.0% | ||
| Q4 24 | -18.7% | -41.3% | ||
| Q3 24 | -11.8% | -28.9% | ||
| Q2 24 | 3.3% | -55.9% | ||
| Q1 24 | -3.8% | -22.1% |
| Q4 25 | 2.3% | 9.9% | ||
| Q3 25 | 1.2% | 3.9% | ||
| Q2 25 | 0.9% | 2.4% | ||
| Q1 25 | 2.2% | 2.2% | ||
| Q4 24 | 2.4% | 9.4% | ||
| Q3 24 | 1.9% | 2.2% | ||
| Q2 24 | 3.2% | 2.9% | ||
| Q1 24 | 2.6% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
